Bioretec Ltd Proposes New Board Member Candidates for 2026
On January 30, 2026, Bioretec Ltd announced significant proposals for its upcoming Annual General Meeting (AGM) scheduled on May 8, 2026. These recommendations come from the Shareholders' Nomination Board, underscoring the company's commitment to solid governance and strategic growth.
Remuneration for Board Members
In efforts to maintain a capable leadership team, the Shareholders' Nomination Board has recommended remuneration for Board members for the term beginning at the conclusion of the 2026 AGM and extending until the next AGM in 2027. The proposals include:
- Chairperson of the Board: EUR 3,750 per month;
- Deputy Chairperson of the Board: EUR 2,500 per month, contingent upon election as the Deputy Chairperson;
- Board members: EUR 2,000 per month.
The Company also plans to reimburse reasonable travel expenses for the Board members, adhering to guidelines set by the Tax Administration.
Proposed Board Composition
The Shareholders' Nomination Board has proposed maintaining the current structure of six members for the Board of Directors in 2026. For the past year, the Board comprised six members until the recent resignation of Sarah van Hellenberg Hubar-Fisher, who transitioned to Chief Executive Officer of Bioretec. As of December 31, 2025, the Board consists of five members.
Election of New Board Members
The nomination process includes re-elections and new nominations:
- Re-elected members include:
- B.Sc. Microbiology, BBA Michael Piccirillo
- LL.M Päivi Malinen
- M.Sc. (Econ) Kustaa Poutiainen
- Doctor of Science (Technology) Antti Vasara
- MD Justin Barad
- New Board member nomination:
- MBA, BS David Gill
The proposed members have undergone assessment and are deemed mostly independent from Bioretec and its major shareholders, with an exception for Kustaa Poutiainen, who maintains independence from Bioretec but has ties with significant shareholder Stephen Industries Inc Oy.
Nomination Board Composition
To ensure a diverse and competent Board, the Shareholders' Nomination Board consists of:
- Tor-Oskar Karlberg from Stephen Industries Inc Oy (Chair)
- Rami Vehmas from Ilmarinen Mutual Pension Insurance Company
- Heinz Moitzi from W&M GmbH
Kustaa Poutiainen serves as an expert advisor to the Nomination Board, bringing additional insight into the nominations.
Future Outlook and Strategic Vision
Bioretec's commitment to innovation and leadership in orthopedic care is emphasized through the diverse abilities of its Board. By ensuring the right mix of skills and expertise, the company is positioned to advance its strategic objectives effectively.
In addition to Board matters, Bioretec continues to lead with groundbreaking technologies in orthopedic implants. Known for producing biodegradable implants that facilitate enhanced bone healing, Bioretec is recognized for its RemeOs™ product line. These cutting-edge materials introduce new solutions for better surgical outcomes, with safety and efficacy backing their use in approximately 40 countries.
Moreover, Bioretec's Activa line of implants showcases innovation in fully bioabsorbable products, tailored for a range of medical requirements across patient demographics. The company remains committed to transforming medical device practices with solutions that are not only effective but cognizant of patient comfort.
For updates on Bioretec's advancements and board activities, individuals are encouraged to stay in touch with the company's communications and reports.
Frequently Asked Questions
What proposals will be presented at the AGM of Bioretec in 2026?
The AGM will feature proposals regarding the remuneration of Board members and the election of new members.
Who are the newly nominated candidates for the Board?
David Gill has been proposed as a new member, while several others are nominated for re-election.
How is the independence of the Board members determined?
The independence is assessed based on their connections to Bioretec and its significant shareholders.
What role does the Nomination Board play?
The Nomination Board ensures that appointments to the Board are made based on skills and experience alignment with Bioretec’s goals.
What innovations is Bioretec working on currently?
Bioretec develops biodegradable orthopedic implants like RemeOs™ and Activa, aimed at improving patient outcomes in surgeries.
